H. Lundbeck A/S (0ND5.IL)

34,56 +0,36 (+1,05%) Al cierre: 03:51PM BST

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5600

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Joerg Hornstein	CFO & Exec. VP of Corp. Functions	3,4M	N/A	1977
Mr. Jacob Tolstrup	Exec. VP of Commercial Operations	8,2M	N/A	1972
Mr. Lars Bang	Exec. VP of Product Devel. & Supply	7,7M	N/A	1962
Dr. Per Johan Luthman	Exec. VP of R&D	8,6M	N/A	1959
Mr. Charl van Zyl	Pres & CEO	N/A	N/A	1967
Dr. Tarek Samad Ph.D.	Sr. VP & Head of Research	N/A	N/A	N/A
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	N/A	N/A	N/A
Ms. Elise Hauge	Exec. VP of People & Communication	N/A	N/A	1967
Mr. Ole Chrintz	Sr. VP of International Markets	N/A	N/A	1958
Mr. Keld Flintholm Jorgensen	Exec. VP of Corp. Strategy & Bus. Devel.	N/A	N/A	1971

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en DKK.

Descripción

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Gobierno corporativo

El ISS Governance QualityScore de H. Lundbeck A/S, a día 1 de octubre de 2023, es 2. Las puntuaciones base son Auditoría: 4; Tablero: 3; Derechos de los accionistas: 9; Compensación: 2.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.